Bloodscan Biotech Inc.

BloodScan Biotech Inc. is a biotechnology company specializing in liquid biopsy technology, founded in 2023 by a research team from the University of Michigan. The company develops and commercializes the Labyrinth One—an automated circulating tumor cell (CTC) enrichment system that isolates intact cancer cells directly from blood samples. This microfluidic-based platform enables non-invasive cancer diagnosis, monitoring, and personalized treatment selection across solid tumors from stage 0 to stage 4. The technology achieves near-100% sensitivity in advanced cancers, detects pre-invasive lesions, and delivers 97% genomic concordance with tissue biopsies. BloodScan's innovation addresses critical gaps where traditional tissue biopsy is unsafe, impractical, or impossible, providing clinicians and researchers with biopsy-equivalent insights from a simple blood draw. The company serves clinical diagnostic, research, and precision oncology applications.